Replimune Group (NASDAQ:REPL) Stock Price Up 6.1% – Still a Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded up 6.1% during mid-day trading on Thursday . The stock traded as high as $14.72 and last traded at $14.63. 565,284 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 734,544 shares. The stock had previously closed at $13.78.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Jefferies Financial Group boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets boosted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright upped their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Replimune Group currently has an average rating of “Buy” and an average price target of $19.29.

Replimune Group Stock Down 2.3 %

The firm’s fifty day moving average price is $12.68 and its two-hundred day moving average price is $11.86. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -4.55 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP grew its position in Replimune Group by 156.6% in the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company’s stock worth $10,346,000 after purchasing an additional 521,366 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in Replimune Group in the 4th quarter worth about $2,196,000. Soleus Capital Management L.P. bought a new stake in Replimune Group in the 4th quarter worth about $3,179,000. Two Sigma Investments LP grew its position in Replimune Group by 18.6% in the 4th quarter. Two Sigma Investments LP now owns 212,586 shares of the company’s stock worth $2,574,000 after purchasing an additional 33,346 shares in the last quarter. Finally, Tang Capital Management LLC grew its position in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock worth $32,697,000 after purchasing an additional 1,500,000 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.